vTv Therapeutics Inc. reported a net loss of $26.97 million for the fiscal year ending December 31, 2025, compared to a loss of $18.46 million in the previous year, marking an increase of approximately 48.1%. The company did not generate any revenue from drug sales during this period, with the prior year’s revenue of $1.02 million primarily stemming from milestone payments under collaboration agreements. Total operating expenses rose to $32.81 million, up from $25.20 million in 2024, driven by increased research and development costs associated with the ongoing clinical trials for its lead product candidate, cadisegliatin (TTP399), which is currently in a Phase 3 trial for type 1 diabetes.
The increase in research and development expenses was significant, rising by 54.7% to $17.86 million, largely due to heightened spending on cadisegliatin clinical studies. General and administrative expenses also saw a rise, totaling $14.95 million, reflecting increased share-based compensation and legal costs. The company’s cash and cash equivalents stood at $88.9 million as of December 31, 2025, bolstered by an $80 million gross proceeds from a private placement completed in September 2025, which is expected to fund operations beyond the anticipated topline data readout from the CATT1 trial.
Strategically, vTv Therapeutics has made notable advancements, including an amended licensing agreement with Newsoara Biopharma, which provided a $20 million upfront payment for global rights to its PDE4 inhibitor, HPP737. The company is also exploring additional funding avenues and partnerships to support its drug development pipeline. As of the end of 2025, vTv Therapeutics employed 26 individuals, maintaining a lean operational structure while focusing on advancing its clinical programs.
Looking ahead, vTv Therapeutics anticipates continued losses as it progresses through clinical trials and seeks regulatory approvals for its drug candidates. The company has emphasized the need for additional capital to sustain its operations and fund ongoing research and development activities. The successful commercialization of cadisegliatin and other candidates remains contingent on favorable clinical trial outcomes and regulatory approvals, with the company expressing optimism about its potential to address unmet medical needs in diabetes treatment.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company developing oral treatments for metabolic and inflammatory diseases. Its lead candidate, cadisegliatin, targets type 1 diabetes by improving glycemic control and reducing hypoglycemia risk. The company focuses on innovative mechanisms, strategic collaborations, and international trials to bring first-in-class therapies to market, addressing significant unmet medical needs in diabetes and chronic inflammatory conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.